HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tezacitabine enhances the DNA-directed effects of fluoropyrimidines in human colon cancer cells and tumor xenografts.

Abstract
Tezacitabine is a nucleoside analogue characterized by a dual mechanism of action. Following intracellular phosphorylation, the tezacitabine diphosphate irreversibly inhibits ribonucleotide reductase, while the tezacitabine triphosphate can be incorporated into DNA during replication or repair, resulting in DNA chain termination. In the present study we have investigated the effect of the combination of tezacitabine and 5-fluorouracil (5-FU) or 5-fluoro-2'-deoxyuridine (FUdR) on HCT 116 human colon carcinoma cells and xenografts. We used response surface analysis (RSA) and clonogenic assay to evaluate combination effects of tezacitabine and 5-FU. Tezacitabine is antagonistic when combined with 5-FU in the RSA assay and does not effect the clonogenicity of HCT 116 cells when compared with cells treated with 5-FU alone. However, when combined sequentially with FUdR, tezacitabine leads to potentiation of cell killing in the clonogenic assay, additivity in the RSA assay, and increased apoptosis when compared to FUdR alone, suggesting that cytotoxicity of fluoropyrimidines such as FUdR that have more DNA-directed effects can be potentiated by tezacitabine. We also report that oral administration of the fluoropyrimidine capecitabine, an oral prodrug of 5-FU, in combination with tezacitabine shows statistically significant additivity in the HCT 116 xenograft model. This interaction may be explained by the finding that tezacitabine elevates activity of thymidine phosphorylase (TP), the enzyme required for activation of the capecitabine prodrug in tumors. Our results provide evidence that tezacitabine enhances the DNA-directed effects of fluoropyrimidines in human colon cancer cells and may modulate the antitumor activity of fluoropyrimidines.
AuthorsPietro Taverna, Katherine Rendahl, Dragana Jekic-McMullen, Yi Shao, Kim Aardalen, Fernando Salangsang, Laura Doyle, Eddie Moler, Barbara Hibner
JournalBiochemical pharmacology (Biochem Pharmacol) Vol. 73 Issue 1 Pg. 44-55 (Jan 01 2007) ISSN: 0006-2952 [Print] England
PMID17046720 (Publication Type: Journal Article)
Chemical References
  • Floxuridine
  • Deoxycytidine
  • DNA
  • Thymidylate Synthase
  • Thymidine Phosphorylase
  • Fluorouracil
  • tezacitabine
Topics
  • Apoptosis (drug effects)
  • Cell Line, Tumor
  • Colonic Neoplasms (enzymology, pathology)
  • DNA (drug effects)
  • DNA Damage
  • Deoxycytidine (analogs & derivatives, pharmacology)
  • Floxuridine (pharmacology)
  • Fluorouracil (pharmacology)
  • Humans
  • Thymidine Phosphorylase (metabolism)
  • Thymidylate Synthase (metabolism)
  • Transplantation, Heterologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: